Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362841 | 1.00 | MAOB (0.61) | MAOBGAAMAPTMAOARAB9A | |
| Hydrochloric Acid SCHEMBL1330115 | 0.98 | MAOB (0.59) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL1258945 | 0.82 | APP (0.59) | MAOBMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL11177596 | 0.82 | MAOB (0.59) | MAOBMAOARAB9ALMNACYP1A2 | |
| SCHEMBL11186146 | 0.82 | APP (0.54) | MAOBMAOARAB9ASMN1; SMN2CA12 | |
| SCHEMBL504815 | 0.81 | MAOB (0.60) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL15435397 | 0.81 | NPC1 (0.53) | MAOBMAOARAB9ALMNA | |
| SCHEMBL13535008 | 0.79 | P4HTM (0.60) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL1680607 | 0.79 | MAOB (0.59) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL11183436 | 0.78 | MAOB (0.67) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118206548-A | Synthesis method of [1,2,4] triazolo [1,5-a ] pyridin-6-ol | 江苏工程职业技术学院 | 2024-06-18 | — | — | CN | claimed |
| US-12551580-B2 | Heterocyclic compounds and imaging agents for imaging Huntington protein | CHDI FOUNDATION, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4615839-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4612151-A1 | PREPARATION OF IMIDAZOPYRIDINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-120152973-A | Protein tyrosine phosphatase inhibitors, compositions, and methods of use | 百时美施贵宝公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120092003-A | CDK protein degrading agents, pharmaceutical compositions and therapeutic uses | 拜欧斯瑞克斯公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| US-12234220-B2 | Immunomodulatory compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250034171-A1 | IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2025-01-30 | — | — | US | disclosed |
| US-6951945-B2 | Heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-20040014968-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED THOMAS (US) | 2004-01-22 | — | — | US | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
| EP-0120589-B1 | IMIDAZO-HETEROCYCLIC COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
| US-4450164-A | ANTIULCER AND ANTISECRETORY AGENTS | SCHERING CORPORATION (US) | 1984-05-22 | — | — | US | disclosed |
| US-4406690-A | Certain aralkyloxy or aralkylthio-pyridyl-phthalimides and their use as herbicides | ZOECON CORPORATION (US) | 1983-09-27 | — | — | US | disclosed |
| US-4406689-A | Certain aralkyloxy or thio-pyridyl-imidazo-pyridines and their herbicidal use | ZOECON CORPORATION (US) | 1983-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014968-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | MAOB 3813/4885GAA 589/4885MAPT 4407/4885 |
| US-12234220-B2 | Immunomodulatory compounds | CRBN, CD47, CD58 | MAOB 3653/4885GAA 1182/4885MAPT 1799/4885 |
| US-20250034171-A1 | IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | TPMT, QDPR, BRD4 | MAOB 740/4885GAA 709/4885MAPT 1783/4885 |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | MAOB 3663/4885GAA 384/4885MAPT 4402/4885 |
| US-12551580-B2 | Heterocyclic compounds and imaging agents for imaging Huntington protein | HTT, HYPK, HIRA | MAOB 3676/4885GAA 2749/4885MAPT 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.